New biologic KER-012 shows promise for Hard-to-Treat lung condition
Disease control
Terminated
This phase 2 trial tested an experimental biologic called KER-012 in 113 adults with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. Participants received either KER-012 or a placebo as a shot every 4 weeks, on top of their usual PAH…
Phase: PHASE2 • Sponsor: Keros Therapeutics, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC